Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.
Seqirus, Summit, NJ, United States.
Vaccine. 2019 Sep 16;37(39):5807-5811. doi: 10.1016/j.vaccine.2019.08.024. Epub 2019 Aug 22.
Egg-based influenza vaccines could be less effective than cell-based vaccine due to adaptive mutations acquired for growth. We conducted a test-negative case-control study at Kaiser Permanente Southern California to assess vaccine effectiveness (VE) against hospitalization for laboratory-confirmed influenza during 2017-2018. Among the 1186 cases and 6946 controls, 74% and 59%, respectively, were ages ≥ 65 years. For any influenza, the adjusted relative VE of cell-based vaccine versus egg-based vaccines was 43% (95% CI: -45% to 77%) for patients ages < 65 years and 6% (95% CI: -46% to 39%) for patients ages ≥ 65 years. For influenza A(H3N2), the adjusted relative VE was 61% (95% CI: -63% to 91%) for patients ages < 65 years and -4% (95% CI: -70% to 37%) for patients ages ≥ 65 years. Statistically significant protection against influenza hospitalization of cell-based vaccine compared to egg-based vaccines was not observed, but further studies in additional influenza seasons are warranted.
基于鸡蛋的流感疫苗由于生长过程中获得的适应性突变，其效果可能不如基于细胞的疫苗。我们在 Kaiser Permanente Southern California 进行了一项病例对照研究，以评估 2017-2018 年期间实验室确诊流感住院的疫苗有效性 (VE)。在 1186 例病例和 6946 例对照中，分别有 74%和 59%的患者年龄≥65 岁。对于任何流感，细胞疫苗相对于鸡蛋疫苗的调整后相对 VE 为年龄<65 岁的患者的 43%（95%CI：-45%至 77%），年龄≥65 岁的患者的 6%（95%CI：-46%至 39%）。对于甲型 H3N2 流感，年龄<65 岁的患者的调整后相对 VE 为 61%（95%CI：-63%至 91%），年龄≥65 岁的患者为-4%（95%CI：-70%至 37%）。与鸡蛋疫苗相比，细胞疫苗并未观察到对流感住院的统计学显著保护作用，但有必要在其他流感季节进行进一步研究。
